微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2018, Vol. 10 ›› Issue (5): 393-396.doi: 10.3969/j.issn.1674-5671.2018.05.11

• 临床应用 • 上一篇    下一篇

塞来昔布对鼻咽癌放化疗增敏的作用

  

  1. 广西医科大学第三附属医院肿瘤科
  • 出版日期:2018-10-25 发布日期:2018-12-12
  • 通讯作者: 黄昌杰 E-amil：changjie_huang@163.com
  • 基金资助:

    广西科学研究与技术开发计划资助项目（桂科攻14124004-1-21）

Effect of celecoxib on radiochemotherapy sensitivity of nasopharyngeal carcinoma

  • Online:2018-10-25 Published:2018-12-12

PDF (PC)

646

赞

摘要：

目的  观察塞来昔布对鼻咽癌患者放化疗的增敏作用及安全性。 方法  选择2013年12月至2017年12月广西医科大学第三附属医院收治的73例鼻咽癌患者，按随机数字表法将其分为观察组38例和对照组35例，观察组采用同步放化疗联合塞来昔布治疗，对照组给予同步放化疗治疗，比较两组患者的近期疗效和安全性。结果  观察组患者肿瘤完全缓解率明显高于对照组，差异有统计学意义（57.9% vs 22.8%，χ2=7.849，P=0.005）；两组患者胃肠道反应、放射性损伤、肾功能损伤、骨髓抑制等不良反应发生率比较差异均无统计学意义（P＞0.05）。结论  塞来昔布能提高鼻咽癌患者在同步放化疗中的完全缓解率，可取得较好的近期疗效，患者均可耐受。

关键词: 鼻咽肿瘤, 塞来昔布, Cox-2抑制剂, 放疗, 化疗, 增敏剂

Abstract:

Objective To investigate the effect and safety of celecoxib on radiochemotherapy sensitivity in patients with nasopharyn-geal carcinoma（NPC）. Methods Patients  with nasopharyngeal carcinoma（n=73） were enrolled from  December 2013 to December 2017 and randomly divided into two groups：the control group（n=35） received concurrent chemoradiotherapy，while the experimental group（n=38） received the same chemoradiotherapy in combination with celecoxib. The short-term efficacy and safety were compared between the two groups. Results The complete response rate in the experimental group was significantly higher than that in the control group（57.9% vs  22.9%，χ2=7.849，P=0.005），and the adverse reactions such as gastrointestinal reactions, radiation injury，renal dysfunction，and myelosuppression were  similar between the two groups(P＞0.05). Conclusions Celecoxib combined with radiochem-otherapy show better complete response rate and good short-term efficacy for nasopharyngeal carcinoma，and it is well tolerated.

Key words: Nasopharyngeal neoplasms, Celecoxib, Cox-2 inhibitors, Radiotherapy, Chemotherapy, Sensitizer